BiotechTube
Thelper

Thelper

Oslo, Norway· Est.
thelper.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Thelper AS is an Oslo-based biotech pioneering a novel approach to cancer therapy by targeting virally encoded proteins within solid tumors. Its platform focuses on developing antiviral antibody-drug conjugates (ADCs) designed for high tumor specificity and reduced toxicity. The company is in the preclinical stage, has secured seed funding and a research grant, and is led by a founder with strong clinical and industrial experience. Its strategy addresses a significant unmet need in aggressive, metastatic cancers with limited treatment options.

Oncology

Technology Platform

Platform for developing first-in-class antiviral antibody-drug conjugates (ADCs) targeting novel viral proteins highly expressed in solid tumors and their immunosuppressive microenvironment, using next-generation linkers for improved specificity and safety.

Opportunities

Thelper operates in the high-growth ADC market, targeting a significant unmet need in aggressive, metastatic solid tumors.
Its unique focus on a viral biomarker offers potential for high specificity, a favorable safety profile, and intellectual property distinct from common cellular targets.
The approach could be applicable across multiple tumor types expressing the viral protein.

Risk Factors

The company faces high scientific risk as its novel viral target hypothesis is unproven in the clinic.
As a preclinical, pre-revenue biotech with limited seed funding, it carries substantial financial and operational risk, dependent on raising future capital.
It also competes in a crowded and technically challenging ADC landscape dominated by large players.

Competitive Landscape

Thelper competes in the competitive ADC therapeutics space, dominated by large pharma (e.g., AstraZeneca, Pfizer, Roche) and numerous biotechs. Its primary differentiation is targeting a novel class of viral antigens, potentially avoiding direct competition with ADCs targeting HER2, TROP2, or other common tumor-associated antigens. However, it must still demonstrate superior efficacy or safety to gain market share.

More companies in Biologics / Biosimilars →More companies in Norway →